These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 27956417)
61. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211 [TBL] [Abstract][Full Text] [Related]
62. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021 [TBL] [Abstract][Full Text] [Related]
63. Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification. Hashimoto H; Saito M; Kanda N; Yamamoto T; Mieno M; Hatakeyama S BMC Pharmacol Toxicol; 2017 Nov; 18(1):74. PubMed ID: 29179737 [TBL] [Abstract][Full Text] [Related]
64. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201 [TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Fetterly GJ; Ong CM; Bhavnani SM; Loutit JS; Porter SB; Morello LG; Ambrose PG; Nicolau DP Antimicrob Agents Chemother; 2005 Jan; 49(1):148-52. PubMed ID: 15616289 [TBL] [Abstract][Full Text] [Related]
66. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070 [TBL] [Abstract][Full Text] [Related]
67. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. Dixon-Jimenez AC; Brainard BM; Brooks MB; Nie B; Arnold RD; Loper D; Abrams JC; Rapoport GS J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):619-29. PubMed ID: 27599304 [TBL] [Abstract][Full Text] [Related]
68. A Retrospective Analysis of the Effect of Tigecycline on Coagulation Function. Leng B; Xue YC; Zhang W; Gao TT; Yan GQ; Tang H Chem Pharm Bull (Tokyo); 2019; 67(3):258-264. PubMed ID: 30828002 [TBL] [Abstract][Full Text] [Related]
69. Hemolysis interference in 10 coagulation assays on an instrument with viscosity-based, chromogenic, and turbidimetric clot detection. Hedeland Y; Gustafsson CM; Touza Z; Ridefelt P Int J Lab Hematol; 2020 Jun; 42(3):341-349. PubMed ID: 32190991 [TBL] [Abstract][Full Text] [Related]
71. Intravenous lipid emulsion interference in coagulation testing: an De Baerdemaeker K; Foxton E; Wood DM; Archer JRH; Layne K; Wolfe C; Dargan PI Clin Toxicol (Phila); 2024 Jul; 62(7):441-445. PubMed ID: 38958109 [TBL] [Abstract][Full Text] [Related]
72. The Acute Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers: A Randomized Trial. Kimura R; Schwartz JA; Romeiser JL; Senzel L; Galanakis D; Halper D; Bennett-Guerrero E J Appl Lab Med; 2024 May; 9(3):468-476. PubMed ID: 38300838 [TBL] [Abstract][Full Text] [Related]
73. Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation. Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F Antimicrob Agents Chemother; 2014; 58(4):2059-66. PubMed ID: 24449768 [TBL] [Abstract][Full Text] [Related]
74. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies. Nielsen ST; Strandkjær N; Juul Rasmussen I; Hansen MK; Lytsen RM; Kamstrup PR; Rode L; Goetze JP; Iversen K; Bundgaard H; Frikke-Schmidt R Clin Chem Lab Med; 2022 Jan; 60(2):261-270. PubMed ID: 34752018 [TBL] [Abstract][Full Text] [Related]
75. Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections. Schulz LT; Dworkin E; Dela-Pena J; Rose WE Pharmacotherapy; 2018 Jan; 38(1):152-159. PubMed ID: 29121395 [TBL] [Abstract][Full Text] [Related]
77. Evidence for an ethanol mediated disruption of hemostasis. Lox C; Heine MW Gen Pharmacol; 1983; 14(3):377-9. PubMed ID: 6873630 [TBL] [Abstract][Full Text] [Related]
78. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience. Brownell LE; Adamsick ML; McCreary EK; Vanderloo JP; Ernst EJ; Jackson ER; Schulz LT Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):13-19. PubMed ID: 32592120 [TBL] [Abstract][Full Text] [Related]
79. Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study. Anastasio PJ; Wolthoff P; Galli A; Fan W Infect Dis Ther; 2017 Mar; 6(1):115-128. PubMed ID: 28078655 [TBL] [Abstract][Full Text] [Related]